Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652480 | 0.92 | MAPT (0.58) | MAPTLMNAALDH1A1DRD2KMT2A | |
| SCHEMBL31334600 | 0.86 | MAPT (0.52) | MAPTLMNAALDH1A1DRD2KMT2A | |
| SCHEMBL30981132 | 0.86 | MAPT (0.56) | MAPTLMNAALDH1A1DRD2GALR3 | |
| SCHEMBL4822596 | 0.86 | ALDH1A1 (0.61) | MAPTLMNAALDH1A1DRD2HTR1A | |
| SCHEMBL27178664 | 0.84 | HTR1A (0.56) | MAPTLMNAGALR3HTR1AKMT2A | |
| SCHEMBL4823574 | 0.81 | ALDH1A1 (0.55) | MAPTLMNAALDH1A1DRD2HTR1A | |
| SCHEMBL30965752 | 0.81 | MAPT (0.55) | MAPTLMNAALDH1A1DRD2GALR3 | |
| SCHEMBL4516920 | 0.78 | MAPT (0.56) | MAPTLMNAALDH1A1DRD2GALR3 | |
| SCHEMBL29106557 | 0.78 | ALDH1A1 (0.55) | MAPTLMNAALDH1A1DRD2KMT2A | |
| SCHEMBL30198676 | 0.78 | CKS1B (0.54) | MAPTDRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | MAPT 2494/4885LMNA 1912/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.